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Abstract
Introduction Amplification of the TNK2 gene in primary tumours
correlates with poor prognosis. In accordance, TNK2
overexpression was shown to promote invasion of cancer cells
– but the mechanism by which TNK2 mediates these effects is
unresolved. TNK2 was suggested to regulate Cdc42-driven
migration by activation of breast cancer antioestrogen
resistance 1 (BCAR1); however, distinct from this effect is
evidence for a role of TNK2 in the regulation of epidermal growth
factor receptor (EGFR) endocytosis and degradation. In the
present study we sought to investigate whether negative
targeting of TNK2 by siRNA could be used to inhibit cancer cell
invasion, to establish the contribution of its effect on the EGFR
and to consequently attempt to resolve the issue of TNK2's
mechanism of action.
Methods We used siRNA to knockdown expression of TNK2
and its proposed effector BCAR1 in order to analyse the effect
of this knockdown on cancer cell behaviour in vitro. We
examined morphological changes using phase-contrast
microscopy and immunohistochemistry. Functional parameters
examined included apoptosis, proliferation, migration and
invasion. We also performed flow cytometry analysis to examine
EGFR cell surface expression and carried out western blot to
examine the total EGFR levels.
Results We observed that targeting of TNK2 by siRNA in breast
cancer cells resulted in distinct morphological changes
characterised by a stellate appearance and an absence of
protrusions at membrane edges. These changes were not
recapitulated upon siRNA targeting of BCAR1. We thus
hypothesised that a component of the effects induced by TNK2
may be independent of BCAR1. Consistent with the idea of an
alternative mechanism for TNK2, we observed that TNK2
associates with activated EGFR in breast cancer cells in a
TNK2-kinase-independent manner. Furthermore, we
demonstrated that TNK2 functions to maintain EGFRs on the
cell surface. We could demonstrate that the main functional
effect of activating these surface EGFRs in breast cancer cells
is stimulation of migration. In accordance, TNK2 silencing by
siRNA led to a significant reduction in cell surface EGFR and to
a concomitant decrease in the migratory and invasive capacity
of breast cancer cells.
Conclusion Our data suggest that TNK2 can enhance
migration and invasion of breast cancer cells via preservation of
EGFR expression, notwithstanding its previously reported
signalling via BCAR1, explaining its oncogenic behaviour in vitro
and correlation with metastatic human breast cancer in vivo.
Introduction
The human epidermal growth factor receptor (EGFR) is over-
expressed in up to 20% of patients diagnosed with breast can-
cer and is associated with reduced survival [1,2]. The work on
molecular profiling of invasive breast cancer has led to the
identification of at least five distinct subtypes in which the
most invasive and malignant type is entitled basal-like breast
cancer [3]. This molecular subtype is predominantly oestrogen
receptor alpha-negative, progesterone receptor-negative,
human epidermal growth factor receptor 2-negative and
EGFR-positive. The basal-like subtype is linked with poor clin-
ical outcome and represents the most likely subgroup of
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breast tumours that could benefit from EGFR targeted therapy
as they lack the other conventional receptor drug targets [3-5].
Similar to other receptor drug targets, however, clinical resist-
ance to EGFR inhibitors or monoclonal antibodies is known to
occur [6]. Developing alternative drug targets in the EGFR sig-
nalling pathway as means to treat EGFR-dependent invasive
and metastatic breast cancer is therefore imperative.
Increased migration is a crucial component of increased inva-
sion and metastasis of cancer cells. Key signalling molecules
in the regulation of normal cell as well as cancer cell migration
are the Rho GTPases, most notably Rho, Rac and Cdc42 [7].
Indeed, the acquisition of motile and invasive properties is a
prerequisite to the development of a metastatic phenotype.
These properties are dependent on the RhoGTPases, which
are most widely recognised for their role in dynamic cytoskel-
etal remodelling [8,9]. RhoGTPases control diverse down-
stream actions through distinct effector proteins. Transfection
of T47D breast cancer cells with constitutively active Cdc42
has been shown recently to drive migration via the Cdc42-spe-
cific effector TNK2 (formally known as Ack1), which binds to
activated cdc42 but not to Rho or Rac, and subsequent acti-
vation of breast cancer antioestrogen resistance 1 (BCAR1)
(formally known as p130Cas) [10,11]. (Some confusion has
arisen in the literature regarding the nomenclature and identity
of Ack1 – we herein refer to human Ack1 (NCBI Entrez
GeneID 10188) as TNK2; it is not equivalent to Ack2, of which
there is in fact no such human gene, but was originally the
name of a bovine homologue of Ack1 [14].) TNK2 has also
been suggested to function as an oncogene when overex-
pressed [12,13]. This hypothesis was supported by the find-
ing that amplification of the TNK2 gene and mRNA, in primary
tumours, correlates with poor prognosis [13].
Cdc42 has been linked previously with EGFR function. Cdc42
is proposed to function in a positive feedback loop with the
EGFR whereby epidermal growth factor (EGF) stimulates acti-
vation of Cdc42 and its interaction with specific target pro-
teins: Cdc42, in turn, inhibits EGFR degradation by preventing
binding of c-Cbl to EGFR. This leads to aberrant accumulation
of EGFR on the cell surface and subsequent malignant trans-
formation [15].
Interestingly, TNK2 – a downstream effector of Cdc42 – can
also be activated in response to EGF and interacts with EGFR
via a previously characterised EGFR binding domain [16]. It
has also been reported, however, that TNK2 regulates clath-
rin-mediated EGFR endocytosis and facilitates receptor deg-
radation [17-19]. While Cdc42 maintains EGFR on the cell
surface, therefore, TNK2 in contrast has paradoxically been
reported to facilitate degradation, which is at odds with its
potential role as an oncogene [15,20]. Importantly, no func-
tional effects of the TNK2/EGFR interaction have been estab-
lished in a cancer context to date – and, more importantly, it is
not known how aberrant expression of EGFRs often found in
cancer cells affects this protein–protein interaction.
In the present article we demonstrate the efficacy of targeting
TNK2, a nonreceptor tyrosine kinase, by siRNA, and its effect
on inhibiting EGFR cell surface expression and the migration
and invasion of breast cancer cells. Significantly we found that
silencing of BCAR1, a proposed downstream mediator of
TNK2, inhibits breast cancer cell invasion via a mechanism dis-
tinct from the EGFR.
Materials and methods
Cell culture and transfection
MCF-7, MDA-MB-231 and MDA-MB-468 breast cancer cells
(American Type Culture Collection, Manassas, VA, USA) were
cultured in DMEM supplemented with 10% FBS, 500 U/ml
penicillin 500 μg/ml, and 2 mM L-glutamine. Transient trans-
fection of siRNA was carried out using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA). Subconfluent cells were
washed twice in PBS and once in Optimem (Invitrogen,
Carlsbad, CA, USA) medium, and were incubated with a com-
plex of Lipofectamine 2000 and siRNA in Optimem (at a final
concentration of 100 nM siRNA) for a period of 3 hours. Cells
were then washed twice in PBS and the normal antibiotic and
FBS-containing DMEM medium was replaced.
Subsequent experiments were carried out a minimum of 48
hours following transfection to ensure efficient silencing of the
targeted protein. For all subsequent assays performed, down-
regulation of the protein of interest by siRNA was ensured by
western blot analysis. For plasmid transfection, the procedure
was the same except that subsequent experiments were car-
ried out from 24 hours post-transfection. The wildtype, kinase-
deficient and constitutively active Wt-TNK2, Ca-TNK2 and Kd-
TNK2 constructs were kindly provided by Takaya Satoh (Kobe,
Japan) [21].
Reagents
Antibodies were obtained from the following: mouse mono-
clonal TNK2 (1/300) (Santa Cruz Biotechnology, Santa Cruz,
CA, USA); fluorescein isothiocyanate-conjugated rat mono-
clonal EGFR for fluorescence-activated cell sorting (FACS)
analysis (1/100) (Abcam, Cambridge, UK); mouse monoclonal
EGFR (1/1,000), mouse monoclonal p-EGFR (1/1,000) and
mouse monoclonal BCAR1 (1/2,000) (BD Biosciences, Bed-
ford, MA, USA); mouse monoclonal β-actin (1/25,000)
(Sigma-Aldrich, Saint Louis, MO, USA); and Alexa-Fluor 488
Phalloidin (1/500) (Invitrogen, Carlsbad, CA, USA). Recom-
binant human EGF and the caspase substrate Ac-DEVD-amc
were purchased from Upstate (Lake Placid, NY, USA).
Predesigned siRNAs targeting human TNK2 (#103419,
#124657) and BCAR1 (#21608, #21699) and nontargeting
negative control siRNA (#4611) were purchased from Ambion
(Cambridgeshire, UK). The Biocoat Matrigel Invasion assaysAvailable online http://breast-cancer-research.com/content/10/2/R36
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were purchased from BD Biosciences. PD153035 was pur-
chased from Calbiochem (La Jolla, CA, USA). Alamar Blue rea-
gent for proliferation assay was purchased from Serotec
(Oxford, UK). 4',6-Diamidino-2-phenylindole was purchased
from Sigma. Hoechst 34580 was purchased from Invitrogen.
Immunoblotting and immunoprecipitation
For western blotting, cultured cells were lysed directly in Lae-
mmli buffer with dithiothreitol and were boiled. For immunopre-
cipitation, cells were scraped into PBS and the cell pellet was
then lysed with buffer containing 100 mM Tris–HCl (pH 7.5),
1% Triton X-100, 5 mM ethylenediamine tetraacetic acid, 5
mM EGTA, 50 mM NaCl, 4 mM Na3VO4, 20 μg aprotinin/ml,
1 μg leupeptin/ml, 2.5 mM benzamidine, and 2 mM Pefabloc
(Roche, Basel, Switzerland). The lysates were precleared with
protein-A Sepharose for 1 hour at 4°C, and immunoprecipita-
tions were performed with beads preconjugated with the
immunoprecipitating antibody with constant agitation for 2
hours at 4°C. The beads were washed five times in ice-cold
wash buffer (50 mM HEPES (pH 7.4), 1% Triton X-100, 0.1%
SDS, 150 mM NaCl, 2 mM Na3VO4) and were boiled immedi-
ately in Laemmli buffer with dithiothreitol.
Proteins were separated by SDS-PAGE under reducing con-
ditions and were then transferred to polyvinyldifluoride mem-
branes by electroblotting. The membranes were blocked with
4% powdered milk in PBS 0.1% Tween 20 (PBS-Tween) at
room temperature (RT) for 30 minutes and then probed with
primary antibodies diluted in 2% powdered milk in PBS-Tween
overnight at 4°C or 2 hours at RT. The membranes were then
washed three times with PBS-Tween and probed with horse-
radish peroxidase-conjugated secondary antibodies at
1:10,000 dilutions in 4% powdered milk in PBS-Tween for 1
hour at RT. Following washing three times with PBS-Tween,
the membranes were developed with the enhanced chemilu-
minescence western blotting detection system (Pierce Bio-
tech, Rockford, IL, USA).
Immunocytochemistry
Following siRNA transfection (at least 48 hours), cells were
transferred to chamber slides (BD Biosciences) and were
allowed to adhere overnight. Cells were then washed in PBS
and fixed in 4% paraformaldehyde for 10 minutes at RT. The
cells were then again washed in PBS and permeabilised in
0.5% Triton-X in PBS for 5 minutes at RT. Cells were then
incubated in a blocking solution of 3% BSA/PBS-Tween until
staining was performed. Actin filaments were stained with
Alexa-Fluor 488-conjugated Phalloidin (1/500) in blocking
solution at 4°C overnight or for 2 hours at RT. Following wash-
ing five times with PBS-Tween, cell nuclei were stained with
10 μg/ml 4',6-diamidino-2-phenylindole in blocking solution
for 10 minutes at RT. Cells were washed for a final time with
PBS before coverslips were mounted with a fluorescence
mounting medium and the slides were photographed.
Apoptosis assays
Caspase-3 assay
Cells for analysis per timepoint were divided into 60 mm cul-
ture dishes. At the indicated timepoints, cells were harvested
with 200 μl caspase lysis buffer (10 mM Tris–HCl, pH 7.4, 10
mM NaH2PO4/Na2HPO4, pH 7.4, 130 mM NaCl, 0.1% Triton-
X, and 10 mM NaPPi). Floating cells were collected and
pooled with the lysate. The lysate was divided to perform the
assay in triplicate in a 96-well plate. The lysate protein concen-
tration was measured to ensure equal amounts of protein were
used. To each sample well, 50 μl lysate, 150 μl reaction buffer
(20 mM HEPES, pH 7.5, 10% glycerol, and 2 mM dithiothrei-
tol), and 3 μl caspase substrate Ac-DEVD-amc in dimethylsul-
foxide (Upstate) was added. The reaction mixture was
incubated at 37°C for 1 hour, and thereafter fluorescence was
measured with a Fluostar plate reader (BMG Lab Technolo-
gies, Offenburg, Germany) using excitation and emission
wavelengths of 390 nm and 460 nm, respectively.
Hoechst staining
Cells were seeded onto glass coverslips and, at the indicated
timepoints, were washed once with PBS, fixed for 15 minutes
in 4% paraformaldehyde, washed again with PBS, and then
incubated with Hoechst 34580 at a final concentration of 5
μg/ml at RT for 10 minutes. Following the staining procedure,
cells were washed with PBS before coverslips were mounted
with a fluorescence mounting medium (Dako, Glostrup, Den-
mark). Nuclear morphology was examined and 200 cells were
counted per treatment.
Proliferation assay
A sample of 1,000 MDA-MB-231 cells or 2,000 MCF-7 cells
in 196 μl DMEM (containing 10% serum or serum free) with or
without EGF (100 ng/ml) were seeded in each well of a 96-
well plate. Alamarblue (4 μl) was then added directly to the
wells. These plates were incubated for 2 hours at 37°C before
making the initial measurement (timepoint 0). Fluorescence
was measured using excitation and emission wavelengths of
540 nm and 590 nm, respectively.
Epidermal growth factor receptor internalisation 
analysis
Cells were serum-starved overnight (16 hours), followed by
EGF (100 ng/ml) stimulation for the time periods specified at
37°C. Following this treatment, cells were detached using
Versene (Invitrogen), and washed in FACS buffer (PBS con-
taining 0.5% BSA and 2 mM ethylenediamine tetraacetic acid)
while incubated on ice. Fluorescein isothiocyanate-conjugated
EGFR antibody was added to the cells resuspended in 100 μl
FACS buffer for a period of 1 hour in the dark at 4°C. One
sample to be used as a negative control for background signal
was not incubated with antibody. The cells were then washed
twice in 2 ml FACS buffer and resuspended in a volume of 300
to 600 μl for analysis. The sample remained on ice until the
end of the procedure. Samples were run on the BDBreast Cancer Research    Vol 10 No 2    Howlin et al.
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Facscalibur system (BD Biosciences, Bedford, MA, USA) and
the data analysed using CellQuest software (BD Bio-
sciences). The percentage of cell surface receptors was cal-
culated by setting the value for the negative control siRNA (N)
at 100% cell surface receptor at timepoint 0; the other values
were extrapolated from this value.
Migration assay
Cells were grown to confluence, scratched with a pipette tip,
and washed twice in PBS to remove floating cells. When the
EGFR inhibitor PD153035 (1 μM) was used, cells were
treated for 60 minutes prior to the addition of EGF (100 ng/
ml). As the wound healed over a period of up to 48 hours
depending on the cell type, the cells were photographed at
intervals using an inverted microscope; the sizes of the
wounds were subsequently analysed with the Image J pro-
gram, 1.37v (National Institutes of Health, Bethesda, MD,
USA).
Invasion assay
Cells were counted 48 hours post transfection and equal num-
bers were added to invasion chambers essentially as
described in the manufacturer's protocol (Biocoat Matrigel
Invasion; BD Biosciences). Invasion typically proceeded over
48 hours, and the cells were stained and counted thereafter as
described. Lysates of the cells used for the invasion assays at
the beginning and end of the experiment were taken for west-
ern blot analysis to ascertain the efficiency of the siRNA trans-
fection in each case.
Statistical analysis
Statistical analyses were performed using Microsoft Excel.
Statistical significance was determined using a two-tailed Stu-
dent's t test. Replicates in the assays used are biological rep-
licates representing repetition of the experiments following a
minimum of three separate transfections or treatments.
Results
Downregulation of TNK2 by siRNA in human breast 
cancer cells results in unique cytoskeletal and 
morphological changes
Initially, upon treatment of MDA-MB-231 breast cancer cells
with siRNA directed against TNK2, we observed morphologi-
cal changes by 48 hours post transfection – indicative of
cytoskeletal remodelling – that were characterised by an
increasingly elongated stellate appearance with a distinct
absence of protrusions at the membrane edges (Figure 1a). A
representative western blot is shown illustrating siRNA down-
regulation of TNK2 (S1, S3) relative to the control (N). Surpris-
ingly, however, we noted that these changes were not
recapitulated upon treatment with siRNA targeting the pro-
posed TNK2 downstream effector, BCAR1. This observation
indicated that the effects induced by TNK2 were independent
of BCAR1 (compare TNK2 siRNA (S1) and BCAR1 siRNA
(#3) against the nontargeting control (N) in Figure 1b,i).
Staining for F-actin revealed that TNK2-silenced cells exhib-
ited smooth, straight actin bundles at their membrane edges
(S3 and inset in Figure 1b,ii) in comparison with the protrud-
ing, uneven edges of normal cells or BCAR1-silenced cells (N
and #3 in Figure 1B,ii). A representative western blot is shown
illustrating siRNA downregulation of TNK2 (S1) and BCAR1
(#3) relative to the control (N). Given the previous reported
role of TNK2 in EGFR dynamics [17,19] and the potential
impact of EGFR activation on migration and cytoskeleton
remodelling [22,23], we hypothesised that the EGFR might be
involved in the mechanism of action of TNK2 in breast cancer
cells and hence be related to the observed morphological
phenotype.
TNK2 binds EGFR in a TNK2-kinase-independent 
manner, and the association is enhanced by EGFR 
activation
We examined a range of breast cancer cell lines with varying
levels of EGFR and TNK2. The total protein levels of both
TNK2 and EGFR are shown in Figure 2a; MCF-7 cells have
moderately low EGFR levels relative to MDA-MB-231 cells,
which overexpress EGFR but lack EGFR gene amplification in
contrast to the MDA-MB-468 cell line, which has both
genomic amplification and overexpression of EGFR [24]. We
could demonstrate in serum-starved cells that endogenous
TNK2 binding to endogenous EGFR was enhanced by EGFR
activation (Figure 2b), although the ability of TNK2 to bind
EGFR in normal serum, without EGF stimulation, was also evi-
dent (Figure 2c, lane 1). Furthermore, we found that cells
transfected with wildtype, kinase-deficient or constitutively
active TNK2 have equal ability to immunoprecipitate active
EGFR (Figure 2c, lanes 2 to 4). This observation demonstrates
the novel finding that, although TNK2/EGFR interaction may
be influenced by EGFR activation, it appears to be independ-
ent of TNK2 kinase activity.
Downregulation of TNK2 by siRNA reduces the number of cell
surface EGFRs. To investigate the functional consequences of
the observed TNK2/EGFR interaction, we wanted to examine
how EGFR dynamics might be affected in cancer cells in
which TNK2 had been silenced by siRNA treatment. In partic-
ular, we wanted to investigate the effect on cell surface
EGFRs, as this population of receptors is responsible for initi-
ation of signalling in response to extracellular ligands. Addi-
tionally, this cell surface population has not been examined in
previous reports, which investigated only the total intracellular
levels of EGFR. Accordingly, MDA-MB-231 cells were serum-
starved overnight, incubated with 100 ng/ml EGF for up to 90
minutes and analysed by flow cytometry (FACS) to determine
the relative number of cell surface EGFRs using a fluorescein
isothiocyanate-conjugated antibody.
Although there was little difference in the ability of the TNK2-
silenced cells relative to nontargeting siRNA control cells (N)
to internalise EGFR in response to ligand (Figure 2d; bothAvailable online http://breast-cancer-research.com/content/10/2/R36
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Figure 1
Downregulation of TNK2 by siRNA induces morphological and cytoskeletal changes in human breast cancer cells Downregulation of TNK2 by siRNA induces morphological and cytoskeletal changes in human breast cancer cells. (a) MDA-MB-231 cells 
treated with TNK2-targeting SiRNAs (S1, S3) were observed to undergo morphological changes after transfection relative to the nontargeting 
SiRNA control (N). These changes consisted of an increased elongated appearance and a reduction in the number of protrusions at the membrane 
edges. A representative western blot illustrating the downregulation of TNK2 achieved by siRNA (S1, S3) treatment relative to β-actin is shown. (b) 
The morphology changes observed in TNK2 SiRNA-treated cells were not observed in MDA-MB-231 cells treated with SiRNA directed against 
breast cancer antioestrogen resistance 1 (BCAR1). (i) Cells transfected with nontargeting (N), TNK2-targeting (S1) and BCAR1-targeting (#3) 
siRNA. (ii) The morphological changes induced can also be seen as an alteration in the actin fibre network. Staining for F-actin and costaining for the 
nuclear compartment with 4',6-diamidino-2-phenylindole is shown for cells treated with nontargeting (N), TNK2-targeting (S3) and BCAR1-targeting 
siRNA (#3). A representative western blot illustrating the downregulation of TNK2 (S1) and BCAR1 (#3) achieved by SiRNA treatment relative to β-
actin is shown.Breast Cancer Research    Vol 10 No 2    Howlin et al.
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Figure 2
Epidermal growth factor treatment of breast cancer cells promotes the interaction of TNK2 with EGFR Epidermal growth factor treatment of breast cancer cells promotes the interaction of TNK2 with EGFR. (a) Epidermal growth factor receptor 
(EGFR) and TNK2 have variable protein expression levels in normal and breast cancer cell lines. The levels of TNK2 are shown relative to β-actin pro-
tein levels in the following cell lines: HB2, normal human breast epithelial cells; MCF-7, MDA-MB-468, and T47D human breast cancer cells; HC11 
murine mammary epithelial cells; and human breast cancer cell line, MDA-MB-231. (b) TNK2 is recruited to the EGFR following activation of the 
receptor in MDA-MB-231 cells, as indicated by coimmunoprecipitation in the presence and absence of epidermal growth factor (EGF) stimulation at 
100 ng/ml. (c) The association of EGFR and TNK2 in MDA-MB-231 cells is not dependent on the phosphorylation status of TNK2, as indicated by 
the ability of wildtype (Wt), mutant kinase-deficient (Kd) and constitutively active (Ca) TNK2 to immunoprecipitate activated EGFR. (d) The percent-
age cell surface expression of EGFR is shown in serum-starved MDA-MB-231 cells treated with EGF (100 ng/ml) for the indicated times. Reduced 
numbers of basal cell surface EGFRs are seen in cells treated with targeting SiRNA (S1) relative to the nontargeting SiRNA control (N), as meas-
ured by a fluorescein isothiocyanate-conjugated anti-EGFR antibody by fluorescence-activated cell sorting analysis. On average, a 27% reduction of 
cell surface receptors can be seen at timepoint 0 (P = 0.0135). A representative western blot illustrating the downregulation of TNK2 achieved by 
SiRNA treatment relative to β-actin is shown.Available online http://breast-cancer-research.com/content/10/2/R36
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values fall when exposed to EGF), we found that there was in
fact a significantly reduced number of basal cell surface
EGFRs (timepoint 0) in TNK2-silenced cells (S1) relative to
nontargeting siRNA control cells (N) (Figure 2d). One caveat
is that if we take the relative rates by defining the percentage
of receptors lost over the 90 minutes, there appears to be a
slightly slower rate of internalisation in the TNK2 siRNA-
treated cells. This finding argues that increased internalisation
may not be the mechanism that leads to decreased cell sur-
face EGFR. Of course, the finding may also simply reflect the
fact that, in these cells, a reduced cell surface population
results in a reduced internalisation rate. The experiment was
repeated four times and represents four separate transfec-
tions. On average, a 27% reduction of cell surface receptors
can be seen at timepoint 0 (P = 0.0135) prior to any ligand
stimulation. A representative western blot is shown illustrating
siRNA downregulation of TNK2 (S1) relative to the control (N)
over the course of the experiment.
EGFR activation enhances the migration of breast cancer 
cells with high and low EGFR expression
EGFR activation at the plasma membrane has been proposed
to control or to contribute towards a multitude of cell proc-
esses in normal and cancerous cells, including proliferation
and migration [25]. Because of the effect of TNK2 siRNA on
the cell surface EGFR population, we wanted to determine the
effect of EGFR activation on breast cancer cell behaviour.
Interestingly, we could demonstrate that addition of EGF to
serum-starved cells (or nonstarved cells, data not shown) had
no significant effect on the rate of proliferation over 72 hours
as shown by an Alamar Blue proliferation assay (Figure 3a). In
contrast, we show that activation of EGFR in breast cancer
cells significantly alters the motile properties of these cells.
This was true of cells with high (MDA-MB-231) or low (MCF-
7) relative levels of EGFR. MDA-MB-231 and MCF-7 cells
were allowed to grow to a confluent monolayer, after which a
scratch wound was made using a pipette tip. Migration was
measured as the percentage area refilled over the time peri-
ods, as indicated in Figure 3. The percentage of increased
migration with the addition of EGF was found to be significant
in both cell types (MDA-MB-231 cells, P = 0.0483 and MCF-
7 cells, P = 0.013 at 48 hours in serum-free medium; Figure
3a).
We also confirmed that EGFR activity was responsible for the
effects on migration by use of an EGFR reversible tyrosine
kinase inhibitor, PD153035 [26]. In accordance with our
hypothesis, EGF-stimulated migration was significantly
reduced by PD153035 in both MDA-MB-231 and MCF-7
breast cancer cells (P = 0.0004 and P = 0.0006 at the end
points, respectively; Figure 3c). Inhibition of basal migration in
the presence of PD153035 was also demonstrated in the
absence of additional exogenous EGF. The activation of the
EGFR even by serum-supplemented medium alone therefore
significantly altered the motility of MDA-MB-231 and MCF-7
breast cancer cells (P = 0.028 and P = 0.0264 at the end
points, respectively; Figure 3d).
Reduced cell surface EGFR expression induced by TNK2 
siRNA correlates with reduced migration, but not 
proliferation or apoptosis
Given that the suppression of TNK2 resulted in reduced cell
surface expression of EGFR (Figure 2d), and that activation of
cell surface EGFR is responsible for migration (Figure 3), we
hypothesised that reduced cell surface expression of EGFR,
induced by TNK2 siRNA, should also result in reduced migra-
tion but should not affect apoptosis or proliferation. We con-
sequently investigated the migratory capacity of MDA-MB-
231 and MCF-7 cells transfected with targeting siRNA (S1,
S3) and nontargeting siRNA (N) using the scratch-wound
migration assay. Migration was slower in cells transfected with
targeting siRNA (S1, S3) than control nontargeting siRNA (N),
demonstrating that silencing of TNK2 inhibits human breast
cancer cell migration (Figure 4a for MDA-MB-231 cells; Addi-
tional file 1A for MCF-7 cells). Furthermore, as expected, there
was no significant difference in an Alamar Blue proliferation
assay between the targeting (S1, S3) siRNA-treated cells and
the nontargeting (N) siRNA-treated cells (Figure 4b).
Additionally, caspase-3 activity and Hoechst staining assays
performed indicated no significant differences between the
targeting and nontargeting control in the amount of cells
undergoing apoptosis (Figure 4c,d). These results are consist-
ent with our above observation that the function of EGFR acti-
vation is limited to effects on migration, and verify that
increased apoptosis or decreased proliferation is not respon-
sible for the reduction in migration seen.
BCAR1 siRNA results in reduced invasion without 
causing a reduction in cell surface EGFR expression
Inducing an alteration in the motile properties of cells does not
necessarily reflect an alteration in the invasive capacity of such
cells or indeed reflect a reduced potential to metastasis in
vivo. The ability to demonstrate a reduced propensity to invade
surrounding tissue is therefore paramount for in vivo rele-
vance. Accordingly, we investigated the invasive capacity or
metastatic tendency of these cells using a modified Boyden
chamber coated with Matrigel. At 48 hours following siRNA
transfection, cells were detached, counted, added to the mod-
ified Boyden chambers and allowed to invade the Matrigel-
coated filter for a further 48 hours. The assay was repeated a
total of six times (representing six separate transfections) for
MDA-MB-231 cells, revealing an average inhibition of invasion
of 85.5% (S1) and 91.2% (S3) relative to the nontargeting
siRNA control (N) (Figure 5a). The assay was also performed
on MCF-7 cells (n = 6), revealing an average inhibition of inva-
sion of 33.5% (S1) and 32.7% (S3) relative to the nontarget-
ing siRNA control (N) (see Additional file 1B).Breast Cancer Research    Vol 10 No 2    Howlin et al.
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Interestingly, we noted that MDA-MB-231 cells treated with
BCAR1 siRNA also showed a reduced invasive capacity con-
sistent with the assumption that BCAR1 can regulate cell
migration downstream of TNK2 as previously proposed [10].
An invasion chamber assay experiment revealed an average
inhibition of 52.5% (#2) and 93% (#3) in MDA-MB-231 cells
(Figure 5a). Crucially, however, we found that downregulation
of BCAR1 by siRNA, unlike TNK2 siRNA, did not have a sig-
nificant effect on basal cell surface EGFR expression (Figure
5b).
We also found that the total cellular amount of EGFR was to a
small (~10%), but statistically significant, extent reduced in
response to TNK2 siRNA treatment as examined by western
Figure 3
Epidermal growth factor treatment promotes the migration but not the proliferation of breast cancer cells Epidermal growth factor treatment promotes the migration but not the proliferation of breast cancer cells. (a) Proliferation as measured by an 
Alamar Blue proliferation assay was not significantly affected in serum-starved cells of either cell type over a period of 72 hours. (b) Epidermal 
growth factor (EGF) treatment (100 ng/ml) enhanced MDA-MB-231 cell and MCF-7 cell migration as measured by a scratch-wound migration 
assay. Healing due to cell migration was measured over a period of 48 hours following wounding. The difference in migratory ability induced by EGF 
was significant in both cell types (P = 0.0483 and P = 0.013 at 48 hours for MDA-MB-231 cells and MCF-7 cells, respectively). (c) Treatment of 
both EGF-treated MDA-MB-231 and EGF-treated MCF-7 cells with the epidermal growth factor receptor kinase inhibitor PD153035 (PD) signifi-
cantly inhibited wound healing in serum-containing medium (P = 0.0004 and P = 0.0006 at the end points, respectively). (D) Treatment of both 
MDA-MB-231 cells and MCF-7 cells with PD significantly inhibited wound healing in serum-containing medium (P = 0.028 at 24 hours and P = 
0.0264 at 48 hours, respectively).Available online http://breast-cancer-research.com/content/10/2/R36
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Figure 4
Downregulation of TNK2 by siRNA inhibits human breast cancer cell migration Downregulation of TNK2 by siRNA inhibits human breast cancer cell migration. (a) MDA-MB-231 cells treated with TNK2 targeting SiRNA (S1, 
S3) had less ability to migrate relative to the nontargeting SiRNA control (N) as measured by a scratch-would healing assay. There was a significant 
difference between nontargeting SiRNA control (N) and TNK2-targeting SiRNA (S1) at 4, 8 and 24 hours (P = 0.0195, P = 0.0004 and P = 
0.0002, respectively). There was a significant difference between nontargeting SiRNA control siRNA (N) and TNK2-targeting SiRNA (S3) at 8 hours 
(P = 0.032). Lower panels: representative pictures of the scratch-would assays 48 hours following wounding. (b) Proliferation as measured by an 
Alamar Blue assay was not significantly affected in cells treated with the TNK2-targeting SiRNA (S1, S3) relative to the nontargeting control siRNA 
(N) over a period of 72 hours. (c) Caspase-dependent apoptosis as measured by a caspase-3 cleavage assay showed no significant difference 
between cells treated with the TNK2-targeting SiRNA (S1, S3) relative to the nontargeting control siRNA (N) over a period of 72 hours. Taxol is used 
as a positive control (TAX) and showed significant differences in all cases. (d) There was no significant difference seen for caspase-independent 
apoptosis as measured by Hoechst staining between cells treated with the TNK2-targeting SiRNA (S1, S3) relative to the nontargeting control 
siRNA (N) over a period of 72 hours. Taxol is used as a positive control (TAX) and showed significant differences in all cases. *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001.Breast Cancer Research    Vol 10 No 2    Howlin et al.
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Figure 5
TNK2 controls and BCAR1 control breast cancer cell invasion via distinct mechanisms TNK2 controls and BCAR1 control breast cancer cell invasion via distinct mechanisms. (a) Invasion assays were carried out using MDA-MB-
231 cells transfected with targeting siRNA (S1, S3) and nontargeting SiRNA (N). At 48 hours post transfection, cells were detached, counted, 
added to modified Boyden chambers coated with Matrigel, and allowed to invade over a period of 48 hours. Following this, cells that had invaded 
were fixed in situ, stained and counted. The assay was repeated a total of six times, revealing an average inhibition of invasion of 85.5%, P < 0.0001 
(S1) and 91.2%, P < 0.0001 (S3) relative to the nontargeting SiRNA control (N). A similar effect on the invasive capacity of MDA-MB-231 cells was 
seen in cells treated with SiRNA targeting breast cancer antioestrogen resistance 1 (BCAR1) silencing, where the average inhibition of invasion was 
52.5%, P = 0.0628 (#2) and 93%, P < 0.0001 (#3). A representative image is shown illustrating the cells that had invaded the Matrigel over the 
course of the invasion assay. (b) Effect of targeting TNK2 SiRNA (S1) versus BCAR1 SiRNA (#3) and nontargeting SiRNA (N) on the levels of cell 
surface epidermal growth factor receptors (EGFRs) as measured by fluorescence-activated cell sorting analysis. On average, a 35% reduction of 
cell surface receptors can be seen at timepoint 0 (P = 0.0037) in cells treated with SiRNA targeting TNK2 (S1); however, the reduction seen with 
BCAR1 was not significant (P = 0.156).(c) Effect of TNK2 siRNA treatment on the total cellular EGFR expression as measured by western blot anal-
ysis. Approximately a 10% reduction in total EGFR is observed with TNK2 siRNA treatment. There is no statistically significant reduction seen with 
BCAR1 siRNA treatment. A representative western blot illustrating the downregulation of TNK2 (S1) and BCAR1 (#3) achieved by SiRNA treatment 
and their respective EGFR levels relative to β-actin is shown. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.Available online http://breast-cancer-research.com/content/10/2/R36
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blot analysis at the same timepoint as when reduced cell sur-
face EGFR expression was observed. The graph (Figure 5c)
represents densitometry analysis of six separate transfections.
There was no difference in the total cellular amount of EGFR
in BCAR1 siRNA-treated cells. A representative western blot
is shown, illustrating relative total protein levels in the samples
investigated (Figure 5c).
Discussion
Initially, we observed that targeting of TNK2 by siRNA in
human breast cancer cells resulted in distinct cytoskeletal and
morphological changes, potentially indicative of changes in
the motile properties of these cells. Such changes were not
seen upon siRNA targeting of its proposed downstream effec-
tor BCAR1. This finding led us to hypothesise that the
observed cytoskeletal effects induced by TNK2 must be inde-
pendent of BCAR1. We subsequently observed that TNK2
associates with activated EGFR in breast cancer cells in a
TNK2-kinase-independent manner, and furthermore that it
functions to maintain EGFRs on the cell surface. We contend
that this observation implies TNK2 may ordinarily function
downstream of Cdc42 in the reported positive feedback loop
whereby activated Cdc42 maintains cell surface EGFR
expression [15]. This effect of Cdc42 on EGFR stability has
been previously shown to contribute to enhanced cell migra-
tion by activated Cdc42 [20]. Our data now indicate that the
same is true for TNK2, since the significant reduction of cell
surface EGFRs we observed by TNK2 silencing was accom-
panied by a parallel decrease in the migratory capacity of the
breast cancer cells. We also show that TNK2 siRNA has the
same effect on invasion. In contrast, however, there is no affect
of TNK2 siRNA on proliferation or apoptosis, which is in agree-
ment with our findings that the main functional effect of EGFR
activation in these breast cancer cells is stimulation of motility.
Previous studies claiming that TNK2 functions to promote
degradation of EGFR appear to be at odds with the functional
role of TNK2 in vitro and in vivo and with the results we now
present. One important caveat, however, is that these previous
studies examined total receptor expression in cleared cell
lysates, which does not account for changes in the detergent
insoluble cytoskeletal bound EGFR fraction [17,19]. The
cytoskeleton or actin-bound EGFR fraction is reported to com-
prise the type I, high-affinity EGFRs that are primarily respon-
sible for induction of cellular responses to ligand stimulation at
the cell surface [27-29]. As such, it is imperative that any study
analysing changes in EGFR levels include the cytoskeletal-
bound EGFR fraction. Our results show that the total EGFR
content, including the detergent-insoluble cytoskeletal frac-
tion, is in fact slightly reduced with TNK2 siRNA treatment.
The reduction of EGFR in the whole cell amounts to ~10%,
whereas there is between 27% and 35% of cell surface recep-
tors lost from the cell surface population. The percentage lost
from the surface is higher than the average percentage lost
from the whole cell, indicating that there is actually a selective
reduction in cell surface EGFRs induced by TNK2 siRNA
treatment and that the reduced cell surface receptor content
is not solely as a result of increased EGFR degradation.
In the present study we have established that, even if constitu-
tively active Cdc42 has not been introduced into the cells,
TNK2 silencing alone is sufficient to both inhibit migration and
to reduce the amount of EGFR on the cell surface. We also
show here that BCAR1 siRNA silencing can function to inhibit
invasion of breast cancer cells, even when the cells were not
transfected with constitutively activated Cdc42 as was previ-
ously demonstrated [10]. Importantly, however, we show that
BCAR1 silencing does not effect EGFR basal cell surface
expression, demonstrating a distinct and independent effect of
TNK2. This confirms our hypothesis that TNK2 can operate
separately from BCAR1 to facilitate migration and invasion of
breast cancer cells. Finally, these independent mechanisms
and disparate effects can also explain the discrepancy in the
morphological changes we observed following TNK2 and
BCAR1 siRNA treatments. As EGFR activation can directly
induce morphological changes via cytoskeleton remodelling,
this supports our assertion that the morphological changes we
see with TNK2 but not with BCAR1 siRNA treatment can be
related to the ability to of TNK2 to affect the EGFR.
A prerequisite for classifying a molecule as a target for phar-
macological intervention is demonstrating not only that it
possesses oncogenic properties, but that abolition of its activ-
ity, by selective targeting, actually causes a positive anticancer
effect that could be potentially useful in the treatment of dis-
ease. We have now established the potential of TNK2 in this
regard by a siRNA-silencing approach. It is also of interest to
note the effectiveness of TNK2 silencing in suppressing migra-
tion of not only cells that highly overexpress EGFR, such as
MDA-MB-231 cells, but also those that do not overexpress
EGFR but harbour functional EGFRs, such as the MCF-7
cells. While both MCF-7 and MDA-MB-231 cells expressed
appreciable amounts of TNK2, MCF-7 cells are oestrogen-
responsive breast cancer cells and have low levels of EGFR
while MDA-MB-231 breast cancer cells do not express oes-
trogen receptor alpha, progesterone receptor or human
epidermal growth factor receptor 2 but have very high levels of
EGFR. Both cell lines, as we have shown, respond to EGFR
activation by increased migration. MDA-MB-231 cells, how-
ever, are more reflective of the basal-like subtype of breast
cancer as previously described [3]. Owing to the wide range
of different tumour subcategories and levels of EGFR expres-
sion within basal-like tumours, it is significant that we can dem-
onstrate here the effectiveness of silencing TNK2 even when
the EGFR pathway is active but not hyperactivated.
Conclusion
Based on our present findings we propose that TNK2 may
employ at least two distinct mechanisms to enhance breast
cancer cell migration and invasion, but we note that these areBreast Cancer Research    Vol 10 No 2    Howlin et al.
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not necessarily mutually exclusive. Figure 6 illustrates this
proposition schematically. Furthermore, our findings suggest
that TNK2 is potentially an attractive target for EGFR-depend-
ent cancers or for cancers where the only available drugable
receptor is the EGFR. There remains a need for alternative
drug targets due to the unfortunate reality that the vast majority
of cancers become resistant to conventional drug therapies.
The present study has demonstrated for the first time that
breast cancer cell invasion can be enhanced by the ability of
TNK2 to maintain EGFR cell surface expression and may pro-
vide the impetus for exploration of TNK2 as an alternative drug
target for the treatment of EGFR-dependent cancers. This
potential use is encouraged by the fact that the TNK2–EGFR
interaction is most probably amenable to small peptide inter-
ference, as has been previously demonstrated for the Cdc42–
TNK2 interaction [30,31].
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